Ovarian Cancer - Pipeline Review, H1 2018

  • ID: 4586015
  • Report
  • 2412 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • 3-V Biosciences Inc
  • BioNTech AG
  • Faron Pharmaceuticals Oy
  • Kiromic Inc
  • NuCana Plc
  • RXi Pharmaceuticals Corp
  • MORE
Ovarian Cancer - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Ovarian Cancer - Pipeline Review, H1 2018, provides an overview of the Ovarian Cancer (Oncology) pipeline landscape.

Ovarian cancer is any cancerous growth that may occur in different parts of the ovary. The majority of ovarian cancers arise from the epithelium (outer lining) of the ovary. Signs and symptoms of ovarian cancer include pelvic discomfort or pain, indigestion, gas or nausea, changes in bowel habits, such as constipation, loss of appetite and low back pain. The predisposing factors include age and family history. Treatment includes surgery, chemotherapy and radiation therapy.

Report Highlights:

This latest pipeline guide Ovarian Cancer - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Ovarian Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ovarian Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Ovarian Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 2, 15, 152, 147, 11, 209, 28 and 12 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 12, 15, 47 and 8 molecules, respectively.

Ovarian Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Ovarian Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Ovarian Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Ovarian Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Ovarian Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Ovarian Cancer (Oncology)
Reasons to buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Ovarian Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Ovarian Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • 3-V Biosciences Inc
  • BioNTech AG
  • Faron Pharmaceuticals Oy
  • Kiromic Inc
  • NuCana Plc
  • RXi Pharmaceuticals Corp
  • MORE
Introduction

Ovarian Cancer - Overview

Ovarian Cancer - Therapeutics Development

Ovarian Cancer - Therapeutics Assessment

Ovarian Cancer - Companies Involved in Therapeutics Development

Ovarian Cancer - Drug Profiles

Ovarian Cancer - Dormant Projects

Ovarian Cancer - Discontinued Products

Ovarian Cancer - Product Development Milestones

Appendix

List of Tables

Number of Products under Development for Ovarian Cancer, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Ovarian Cancer - Pipeline by 3-V Biosciences Inc, H1 2018

Ovarian Cancer - Pipeline by 4SC AG, H1 2018

Ovarian Cancer - Pipeline by AB Science SA, H1 2018

Ovarian Cancer - Pipeline by AbbVie Inc, H1 2018

Ovarian Cancer - Pipeline by Adaptimmune Therapeutics Plc, H1 2018

Ovarian Cancer - Pipeline by Adgero Biopharmaceuticals Holdings Inc, H1 2018

Ovarian Cancer - Pipeline by Advenchen Laboratories LLC, H1 2018

Ovarian Cancer - Pipeline by Aeterna Zentaris Inc, H1 2018

Ovarian Cancer - Pipeline by Agenus Inc, H1 2018

Ovarian Cancer - Pipeline by Alethia Biotherapeutics Inc, H1 2018

Ovarian Cancer - Pipeline by AlfaSigma SpA, H1 2018

Ovarian Cancer - Pipeline by Alkermes Plc, H1 2018

Ovarian Cancer - Pipeline by Allist Shanghai Pharmaceutical Technology Co Ltd, H1 2018

Ovarian Cancer - Pipeline by Alpha Cancer Technologies Inc, H1 2018

Ovarian Cancer - Pipeline by Alteogen Inc, H1 2018

Ovarian Cancer - Pipeline by Altor BioScience Corp, H1 2018

Ovarian Cancer - Pipeline by Ambrx Inc, H1 2018

Ovarian Cancer - Pipeline by Amgen Inc, H1 2018

Ovarian Cancer - Pipeline by AnGes Inc, H1 2018

Ovarian Cancer - Pipeline by ANP Technologies Inc, H1 2018

Ovarian Cancer - Pipeline by AntiCancer Inc, H1 2018

Ovarian Cancer - Pipeline by Antigen Express Inc, H1 2018

Ovarian Cancer - Pipeline by Antoxis Ltd, H1 2018

Ovarian Cancer - Pipeline by Aphios Corp, H1 2018

Ovarian Cancer - Pipeline by Aposense Ltd, H1 2018

Ovarian Cancer - Pipeline by Aprea AB, H1 2018

Ovarian Cancer - Pipeline by Arcus Biosciences Inc, H1 2018

Ovarian Cancer - Pipeline by arGEN-X BV, H1 2018

Ovarian Cancer - Pipeline by ARMO Biosciences Inc, H1 2018

Ovarian Cancer - Pipeline by Armour Therapeutics Inc, H1 2018

Ovarian Cancer - Pipeline by ArQule Inc, H1 2018

Ovarian Cancer - Pipeline by Array BioPharma Inc, H1 2018

Ovarian Cancer - Pipeline by Arrien Pharmaceuticals LLC, H1 2018

Ovarian Cancer - Pipeline by Astellas Pharma Inc, H1 2018

Ovarian Cancer - Pipeline by Astex Pharmaceuticals Inc, H1 2018

Ovarian Cancer - Pipeline by AstraZeneca Plc, H1 2018

Ovarian Cancer - Pipeline by Atara Biotherapeutics Inc, H1 2018

Ovarian Cancer - Pipeline by Athenex Inc, H1 2018

Ovarian Cancer - Pipeline by AVEO Pharmaceuticals Inc, H1 2018

Ovarian Cancer - Pipeline by Avipep Pty Ltd, H1 2018

Ovarian Cancer - Pipeline by Basilea Pharmaceutica Ltd, H1 2018

Ovarian Cancer - Pipeline by Bavarian Nordic A/S, H1 2018

Ovarian Cancer - Pipeline by Bayer AG, H1 2018

Ovarian Cancer - Pipeline by BeiGene Ltd, H1 2018

Ovarian Cancer - Pipeline by Bio-Path Holdings Inc, H1 2018

Ovarian Cancer - Pipeline by BioCancell Ltd, H1 2018

Ovarian Cancer - Pipeline by BioEclipse Therapeutics Inc, H1 2018

Ovarian Cancer - Pipeline by BioMoti Ltd, H1 2018

Ovarian Cancer - Pipeline by Bionomics Ltd, H1 2018

Ovarian Cancer - Pipeline by BioNTech AG, H1 2018

Ovarian Cancer - Pipeline by Biscayne Pharmaceuticals Inc, H1 2018

Ovarian Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2018

List of Figures

Number of Products under Development for Ovarian Cancer, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Top 10 Routes of Administration, H1 2018

Number of Products by Stage and Top 10 Routes of Administration, H1 2018

Number of Products by Top 10 Molecule Types, H1 2018

Number of Products by Stage and Top 10 Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • 3-V Biosciences Inc
  • 4SC AG
  • AB Science SA
  • AbbVie Inc
  • Adaptimmune Therapeutics Plc
  • Adgero Biopharmaceuticals Holdings Inc
  • Advenchen Laboratories LLC
  • Aeterna Zentaris Inc
  • Agenus Inc
  • Alethia Biotherapeutics Inc
  • AlfaSigma SpA
  • Alkermes Plc
  • Allist Shanghai Pharmaceutical Technology Co Ltd
  • Alpha Cancer Technologies Inc
  • Alteogen Inc
  • Altor BioScience Corp
  • Ambrx Inc
  • Amgen Inc
  • AnGes Inc
  • ANP Technologies Inc
  • AntiCancer Inc
  • Antigen Express Inc
  • Antoxis Ltd
  • Aphios Corp
  • Aposense Ltd
  • Aprea AB
  • Arcus Biosciences Inc
  • arGEN-X BV
  • ARMO Biosciences Inc
  • Armour Therapeutics Inc
  • ArQule Inc
  • Array BioPharma Inc
  • Arrien Pharmaceuticals LLC
  • Astellas Pharma Inc
  • Astex Pharmaceuticals Inc
  • AstraZeneca Plc
  • Atara Biotherapeutics Inc
  • Athenex Inc
  • AVEO Pharmaceuticals Inc
  • Avipep Pty Ltd
  • Basilea Pharmaceutica Ltd
  • Bavarian Nordic A/S
  • Bayer AG
  • BeiGene Ltd
  • Bio-Path Holdings Inc
  • BioCancell Ltd
  • BioEclipse Therapeutics Inc
  • BioMoti Ltd
  • Bionomics Ltd
  • BioNTech AG
  • Biscayne Pharmaceuticals Inc
  • Boehringer Ingelheim GmbH
  • Boston Biomedical Inc
  • Bristol-Myers Squibb Co
  • Caladrius Biosciences Inc
  • Calithera Biosciences Inc
  • CASI Pharmaceuticals Inc
  • CBT Pharmaceuticals Inc
  • Celgene Corp
  • Celldex Therapeutics Inc
  • Celleron Therapeutics Ltd
  • Cellestia Biotech AG
  • Cellular Biomedicine Group Inc
  • Celon Pharma SA
  • Celprogen Inc
  • Celsion Corp
  • Celyad SA
  • CerRx Inc
  • Chipscreen Biosciences Ltd
  • Cielo Therapeutics Inc
  • Clovis Oncology Inc
  • CohBar Inc
  • Coherus BioSciences Inc
  • Commence Bio Inc
  • Corcept Therapeutics Inc
  • Cotinga Pharmaceuticals Inc
  • Cristal Therapeutics BV
  • Curis Inc
  • Cyclacel Pharmaceuticals Inc
  • CytomX Therapeutics Inc
  • Cytori Therapeutics Inc
  • CZ BioMed Corp
  • DAE HWA Pharmaceutical Co Ltd
  • Daiichi Sankyo Co Ltd
  • DEKK-TEC Inc
  • DelMar Pharmaceuticals Inc
  • Dr. Reddy's Laboratories Ltd
  • Ecrins Therapeutics SAS
  • Eisai Co Ltd
  • Eli Lilly and Co
  • EntreChem SL
  • Epigen Biosciences Inc
  • EpiThany Inc
  • Epizyme Inc
  • Esperance Pharmaceuticals Inc
  • Exelixis Inc
  • F. Hoffmann-La Roche Ltd
  • Faron Pharmaceuticals Oy
  • Fate Therapeutics Inc
  • Five Prime Therapeutics Inc
  • Formation Biologics Inc
  • Forty Seven Inc
  • Fujifilm Holdings Corporation
  • GamaMabs Pharma SA
  • Gene Techno Science Co Ltd
  • Genelux Corp
  • Genentech Inc
  • Genisphere LLC
  • Genmab A/S
  • Gilead Sciences Inc
  • GlaxoSmithKline Plc
  • Glenmark Pharmaceuticals Ltd
  • Glycotope GmbH
  • GP Pharm SA
  • Gradalis Inc
  • GW Pharmaceuticals Plc
  • Halozyme Therapeutics Inc
  • Harbin Gloria Pharmaceuticals Co Ltd
  • Hemispherx Biopharma Inc
  • Horizon Pharma Plc
  • Ideaya Biosciences Inc
  • IGF Oncology LLC
  • Ignyta Inc
  • Ildong Pharmaceutical Co Ltd
  • IMMD Inc
  • Immix BioPharma Inc
  • Immune Design Corp
  • Immune Pharmaceuticals Inc
  • Immunocore Ltd
  • ImmunoGen Inc
  • Immunomedics Inc
  • Immutep Ltd
  • IMPACT Therapeutics Inc
  • Imugene Ltd
  • IMV Inc
  • Incyte Corp
  • Innate Pharma SA
  • Innovation Pharmaceuticals Inc
  • Inovio Pharmaceuticals Inc
  • Integral Molecular Inc
  • Inventiva
  • Iovance Biotherapeutics Inc
  • ITUS Corp
  • JHL Biotech Inc
  • Jiangsu Hengrui Medicine Co Ltd
  • Jiangsu Kanion Pharmaceutical Co Ltd
  • Johnson & Johnson
  • Juno Therapeutics Inc
  • Karyopharm Therapeutics Inc
  • Kazia Therapeutics Ltd
  • Kiromic Inc
  • Kringle Pharma Inc
  • Kyowa Hakko Kirin Co Ltd
  • Laboratoire HRA Pharma SAS
  • Lantern Pharma Inc
  • LATITUDE Pharmaceuticals Inc
  • Leap Therapeutics Inc
  • LegoChem Biosciences Inc
  • Lidds AB
  • Lixte Biotechnology Holdings Inc
  • Loxo Oncology Inc
  • Lycera Corp
  • Lymphocyte Activation Technologies SA
  • MabVax Therapeutics Holdings Inc
  • MacroGenics Inc
  • Madrigal Pharmaceuticals Inc
  • Mateon Therapeutics Inc
  • MaxCyte Inc
  • MaxiVAX SA
  • Mebiopharm Co Ltd
  • MediaPharma SRL
  • MediciNova Inc
  • MedImmune LLC
  • Merck & Co Inc
  • Merck KGaA
  • Merrimack Pharmaceuticals Inc
  • Mersana Therapeutics Inc
  • Merus NV
  • Millennium Pharmaceuticals Inc
  • Minerva Biotechnologies Corp
  • Mirati Therapeutics Inc
  • Molecular Templates Inc
  • Moleculin Biotech Inc
  • Monopar Therapeutics Inc
  • Morphotek Inc
  • Mycenax Biotech Inc
  • NanoVector Inc
  • NantKwest Inc
  • Natco Pharma Ltd
  • NBE-Therapeutics AG
  • Nektar Therapeutics
  • Neovacs SA
  • Nerviano Medical Sciences Srl
  • Neurimmune Holding AG
  • NewLink Genetics Corp
  • Northern Biologics Inc
  • Northwest Biotherapeutics Inc
  • Novartis AG
  • NovaTarg Therapeutics Inc
  • Noviga Research AB
  • Noxopharm Ltd
  • NuCana Plc
  • Oasmia Pharmaceutical AB
  • OBI Pharma Inc
  • Omeros Corp
  • Omnitura Therapeutics Inc
  • OncBioMune Pharmaceuticals Inc
  • Oncobiologics Inc
  • Oncodesign SA
  • Oncolix Inc
  • Oncolytics Biotech Inc
  • OncoMed Pharmaceuticals Inc
  • OncoResponse Inc
  • OncoTartis Inc
  • OncoTherapy Science Inc
  • Oncovir Inc
  • Oncternal Therapeutics Inc
  • Ono Pharmaceutical Co Ltd
  • Opsona Therapeutics Ltd
  • Optimum Therapeutics LLC
  • ORCA Therapeutics BV
  • Oric Pharmaceuticals Inc
  • Oxford BioMedica Plc
  • Pangaea Biotech SL
  • Patrys Ltd
  • PDS Biotechnology Corp
  • PEP-Therapy SAS
  • Pfizer Inc
  • Pharma Mar SA
  • PharmAust Ltd
  • Pharmicell Co Ltd
  • Plexxikon Inc
  • Precision Biologics Inc
  • Propanc Biopharma Inc
  • Protheragen Inc
  • PsiOxus Therapeutics Ltd
  • PTC Therapeutics Inc
  • Puma Biotechnology Inc
  • Recepta Biopharma SA
  • Regeneron Pharmaceuticals Inc
  • Rexahn Pharmaceuticals Inc
  • Rgenix Inc
  • Richter Gedeon Nyrt
  • Rigel Pharmaceuticals Inc
  • RS Research
  • Rubicon Biotechnology Inc
  • RXi Pharmaceuticals Corp
  • Samumed LLC
  • Sanofi
  • Sanofi Pasteur SA
  • SATT North SAS
  • Scancell Holdings Plc
  • SELLAS Life Sciences Group Inc
  • Senhwa Biosciences Inc
  • Sequoia Sciences Inc
  • Siamab Therapeutics Inc
  • Sichuan Kelun Pharmaceutical Co Ltd
  • Sierra Oncology Inc
  • Sillajen Biotherapeutics
  • Sitka Biopharma Inc
  • Soricimed Biopharma Inc
  • Sotio AS
  • Sphaera Pharma Pte Ltd
  • Sumitomo Dainippon Pharma Co Ltd
  • Sun Pharma Advanced Research Company Ltd
  • Supratek Pharma Inc
  • Susavion Biosciences Inc
  • Sutro Biopharma Inc
  • Symic Biomedical Inc
  • Syndax Pharmaceuticals Inc
  • Synergys Biotherapeutics Inc
  • Synthon Holdings BV
  • Syros Pharmaceuticals Inc
  • Tactiva Therapeutics LLC
  • Taiho Pharmaceutical Co Ltd
  • Takeda Pharmaceutical Co Ltd
  • Takis Srl
  • TapImmune Inc
  • Targovax ASA
  • Tarveda Therapeutics Inc
  • TC BioPharm Ltd
  • TCR2 Therapeutics Inc
  • Tesaro Inc
  • TheraTarget Inc
  • Tocagen Inc
  • Tolero Pharmaceuticals Inc
  • TRACON Pharmaceuticals Inc
  • Transgene SA
  • Trovagene Inc
  • Tyrogenex Inc
  • ValiRx Plc
  • Vascular Biogenics Ltd
  • Vectorite Biomedical Inc
  • Verastem Inc
  • VG Life Sciences Inc
  • ViraTherapeutics GmbH
  • Vyriad Inc
  • XuanZhu Pharma Co Ltd
  • Yooyoung Pharm Co Ltd
  • Zymeworks Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll